← Leaderboards
Elisabeth J Cohen
New York University School Of Medicine
$6,899,640
Attributed
$19,986,537
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.7M · FY2016–23$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$19,986,537 · 1
By mechanism
U10$19,986,537 · 1
Top collaborators
- Judith S Hochman8 shared
- Andrea B Troxel6 shared
- Judith D. Goldberg3 shared
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Mark Joseph Mulligan$87,307,980
- Judith S Hochman$132,321,589
- Judith D. Goldberg$13,573,253
- Moriah E Thomason$15,986,733
- Hua Judy Zhong$7,285,128
Others in their field
Top investigators on “Older Patient”
- Laurence H Baker · University Of Michigan At Ann Arbor$123,433,182
- Judith Kasper · Johns Hopkins University$59,756,567
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$57,671,528
- Adrian Hernandez · Duke University$52,852,701
- Electra D. Paskett · Ohio State University$51,143,665
- Gervasio A Lamas · Mount Sinai Medical Center (Miami Beach)$49,698,451
Research focus
Older PatientLifeDiagnosisMasksImproved OutcomeKeratitisCost18 Year OldEye DiseasesLocationHerpes Zoster OphthalmicusImmunocompetentAffectDoseBurden Of IllnessAftercareCaringChickenpoxEnrollmentChronicChronic PainFollow-UpHerpes Zoster DiseaseOral
Grant awards (9)
Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus$2,127,591
U10 · FY2023 · EY · contact PI
Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus$679,231
U10 · FY2022 · EY · contact PI
Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus$1,985,974
U10 · FY2020 · EY · contact PI
Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus$1,424,768
U10 · FY2020 · EY · contact PI
Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus$3,278,651
U10 · FY2019 · EY · contact PI
Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus$3,873,755
U10 · FY2018 · EY · contact PI
Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus$867,421
U10 · FY2018 · EY · contact PI
Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus$2,849,146
U10 · FY2017 · EY · contact PI
Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus$2,900,000
U10 · FY2016 · EY · contact PI